SEER Cancer Stat Facts: Acute Lymphocytic Leukemia. NCI. [Accessed 26th Feb 2023]. https://seer.cancer.gov/statfacts/html/alyl.html

DeAngelo D, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330–42. https://doi.org/10.1200/EDBK_280175.

Article  PubMed  Google Scholar 

Wieduwilt M. Ph+ ALL in 2022: is there an optimal approach? Hematology Am Soc Hematol Educ Program. 2022;2022(1):206–12. https://doi.org/10.1182/hematology.2022000338.

Article  PubMed  PubMed Central  Google Scholar 

Malard F, Mohty M. Acute lymphoblastic leukaemia. The Lancet. 2020;395(10230):1146–62. https://doi.org/10.1016/S0140-6736(19)33018-1.

Article  CAS  Google Scholar 

Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood Adv. 2007;109(9):3676–8. https://doi.org/10.1182/blood-2006-10-052746.

Article  CAS  Google Scholar 

Iacobucci I, Kimura S, Mullighan CG. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J Clin Med. 2021;10(17):3792. https://doi.org/10.3390/jcm10173792.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirabayashi S, Ohki K, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, et al. Tokyo Children’s Cancer Study Group (TCCSG) ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102(1):118–29. https://doi.org/10.3324/haematol.2016.151035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka H, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. https://doi.org/10.1182/blood.2022015850. Updates to the classification of ALL, including provisional entities.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haider M, Anwer F. Genetics, Philadelphia Chromosome. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560689/.

Druker B, Sawyers C, Kantarjian H, Resta D, Reese S, Ford J, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42. https://doi.org/10.1056/NEJM200104053441402.

Article  CAS  PubMed  Google Scholar 

Rowe J, Buck G, Burnett A, Chopra R, Wiernik P, Richards S, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–7. https://doi.org/10.1182/blood-2005-04-1623.

Article  CAS  PubMed  Google Scholar 

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib dasatinib and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27(3):469–71. https://doi.org/10.1200/JCO.2008.19.8853.

Article  CAS  PubMed  Google Scholar 

O’Hare T, Shakespeare W, Zhu X, Eide C, Rivera V, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–12. https://doi.org/10.1016/j.ccr.2009.09.028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Jabbour E, Kantarjian H, Aldoss I, Montesinos P, Leonard J, Gomez-Almaguer E, et al. First report of PhALLCON: a phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). ASCO Plenary Series. 2023;41. https://doi.org/10.1200/JCO.2023.41.36_suppl.398868. First trial to compare ponatinib versus imatinib in Ph+ ALL; ponatinib had significantly more MRD negative remissions.

Eide C, Zabriskie M, Savage Stevens S, Antelope O, Vellore N, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431–43. https://doi.org/10.1016/j.ccell.2019.08.004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wylie A, Schoepfer J, Jahnke W, Cowan-Jacob S, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733–7. https://doi.org/10.1038/nature21702.

Article  CAS  PubMed  Google Scholar 

• Luskin M, Stevenson K, Mendez L, Wang E, Wadleigh M, Garcia J, et al. A phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for BCR-ABL1-positive ALL in adults. Blood. 2021;138:2305. https://doi.org/10.1182/blood-2021-149225. Phase I trial indicating that dual ABL1 kinase inhibition is feasible.

Article  Google Scholar 

Zerbit J, Tamburini J, Goldwirt L, Decroocq J, Cayuela JM, Chapuis N, et al. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(14):3558–60. https://doi.org/10.1080/10428194.2021.1966787.

Article  CAS  PubMed  Google Scholar 

Leonard J, Rowley J, Hayes-Lattin B, Tyner J, Loriaux M, Druker B, et al. Dual targeting of Ph+ ALL with dasatinib and ABT-199 (venetoclax). In: Poster presented at: 57th ASH Annual Meeting; December 2015; Orlando, FL. [abstract taken from Blood. 2015;126(23):1329]. https://doi.org/10.1182/blood.V126.23.1329.1329.

Scherr M, Kirchhoff H, Battmer K, Wohlan K, Lee C, Ricke-Hoch M, et al. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia. 2019;33(6):1313–23. https://doi.org/10.1038/s41375-018-0315-6.

Article  CAS  PubMed  Google Scholar 

Wang H, Yang C, Shi T, Zhang Y, Qian J, Wang Y, et al. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022;12(20). https://doi.org/10.1038/s41408-022-00621-9.

Short N, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, et al. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021;96:e229–32. https://doi.org/10.1002/ajh.26175.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2022;6(6):1742–53. https://doi.org/10.1182/bloodadvances.2021004821.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rousselot P, Coude M, Gokbuget N, Passerini C, Hayette S, Cayuela J, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL. Blood. 2016;128(6):774–82. https://doi.org/10.1182/blood-2016-02-700153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ottmann O, Pfeifer H, Cayuela J, Spiekermann K, Jung W, Beck J, et al. Nilotinib (Tasigna®) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a prospective multicenter trial (EWALL-PH02). Blood. 2018;123:31. https://doi.org/10.1182/blood-2018-99-114552.

Article  Google Scholar 

Wieduwilt M, Yin J, Wetzler M, Uy G, Powell B, Kolitz J, et al. A phase II study of Dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed Ph/BCR-ABL1-positive acute lymphoblastic leukemia (Ph+ ALL): final results of alliance/CALGB study 10701. Blood. 2018;132:309. https://doi.org/10.1182/blood-2018-99-120029.

Article  Google Scholar 

Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo M, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–23. https://doi.org/10.1056/NEJMoa2016272.

Article  PubMed  Google Scholar 

Jabbour E, Short N, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. The Lancet Haematol. 2023;10(1):e24–34. https://doi.org/10.1016/S2352-3026(22)00319-2.

Article  CAS  PubMed  Google Scholar 

Fedullo A, Messina M, Elia L, Piciocchi A, Gianfelici V, Lauretti A, et al. Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2019;104(2). https://doi.org/10.3324/haematol.2018.196055

Sasaki Y, Kantarjian H, Short N, Wang F, Furudate K, Uryu H, et al. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022;36:1253–60. https://doi.org/10.1038/s41375-021-01496-8.

Article  CAS  PubMed  Google Scholar 

Chiaretti S, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo C, et al. Dasatinib-blinatumomab combination for the front-line treatment of adult Ph+ ALL patients. Updated Results of the Gimema LAL2116 D-Alba Trial. Blood. 2019;134:740. https://doi.org/10.1182/blood-2019-128759.

Article  Google Scholar 

Roberts K, Li Y, Payne-Turner D, Harvey R, Yang Y, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15. https://doi.org/10.1056/NEJMoa1403088.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain N, Roberts K, Jabbour E, Patel K, Eterovic A, Chen K, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572–81. https://doi.org/10.1182/blood-2016-07-726588.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sasaki K, Yamauchi T, Semba Y, Nogami J, Imanaga H, Terasaki T, et al. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. Blood. 2022;139(5):748–60. https://doi.org/10.1182/blood.2021012976.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, et al. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023;98(6):848–56. https://doi.org/10.1080/10428194.2023.2197538.

Article  CAS  PubMed